SCHEMBL29817201

SCHEMBL29817201

CC(C)(C)OC(=O)N1CCN(CCNC(=O)COc2cccc(N3CCC(=O)NC3=O)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 4/20 0.50
▸ CRBN Q96SW2 4/20 0.50
▸ HSD17B10 Q99714 1/20 0.47
▸ ACKR3 P25106 1/20 0.45
▸ EPHX2 P34913 5/20 0.45
▸ ALDH1A1 P00352 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ACHE P22303 5/20 0.42
▸ FAAH O00519 4/20 0.42
▸ BCHE P06276 2/20 0.41
▸ VCP P55072 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23120553 1.00 DDB1 (0.50) DDB1CRBNHSD17B10ACKR3EPHX2
Trifluoroacetic Acid SCHEMBL29816949 0.95 DDB1 (0.46) DDB1CRBNHSD17B10ACKR3EPHX2
SCHEMBL23121027 0.88 HSD17B10 (0.48) DDB1CRBNHSD17B10ALDH1A1POLB
SCHEMBL29817191 0.88 DDB1 (0.49) DDB1CRBNKDM4E
SCHEMBL23120906 0.88 DDB1 (0.49) DDB1CRBNKDM4E
SCHEMBL25079570 0.85 DDB1 (0.52) DDB1CRBNEPHX2ALDH1A1KDM4E
SCHEMBL30257613 0.85 DDB1 (0.52) DDB1CRBNEPHX2ALDH1A1KDM4E
SCHEMBL23120512 0.84 HSD17B10 (0.50) DDB1CRBNHSD17B10ALDH1A1ACHE
SCHEMBL29606381 0.84 HSD17B10 (0.50) DDB1CRBNHSD17B10ALDH1A1ACHE
Hydrochloric Acid SCHEMBL23120544 0.83 HSD17B10 (0.49) DDB1CRBNHSD17B10ALDH1A1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220387602-A1 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-08 — — US disclosed
EP-4031247-A1 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE Novartis AG (CH) 2022-07-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220387602-A1 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE JMJD7, MDM2, IDE DDB1 612/4885CRBN 241/4885HSD17B10 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback